 |
|
Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in DiabetesThe SANDS Randomized Trial
Barbara V. Howard, PhD;
Mary J. Roman, MD;
Richard B. Devereux, MD;
Jerome L. Fleg, MD;
James M. Galloway, MD;
Jeffrey A. Henderson, MD, MPH;
Wm. James Howard, MD;
Elisa T. Lee, PhD;
Mihriye Mete, PhD;
Bryce Poolaw, MD;
Robert E. Ratner, MD;
Marie Russell, MD;
Angela Silverman, MSN, CANP;
Mario Stylianou, PhD;
Jason G. Umans, MD, PhD;
Wenyu Wang, PhD;
Matthew R. Weir, MD;
Neil J. Weissman, MD;
Charlton Wilson, MD;
Fawn Yeh, PhD;
Jianhui Zhu, MD
JAMA. 2008;299(14):1678-1689.
Context Individuals with diabetes are at increased risk for cardiovascular disease (CVD), but more aggressive targets for risk factor control have not been tested.
Objective To compare progression of subclinical atherosclerosis in adults with type 2 diabetes treated to reach aggressive targets of low-density lipoprotein cholesterol (LDL-C) of 70 mg/dL or lower and systolic blood pressure (SBP) of 115 mm Hg or lower vs standard targets of LDL-C of 100 mg/dL or lower and SBP of 130 mm Hg or lower.
Design, Setting, and Participants A randomized, open-label, blinded-to-end point, 3-year trial from April 2003-July 2007 at 4 clinical centers in Oklahoma, Arizona, and South Dakota. Participants were 499 American Indian men and women aged 40 years or older with type 2 diabetes and no prior CVD events.
Interventions Participants were randomized to aggressive (n=252) vs standard (n=247) treatment groups with stepped treatment algorithms defined for both.
Main Outcome Measures Primary end point was progression of atherosclerosis measured by common carotid artery intimal medial thickness (IMT). Secondary end points were other carotid and cardiac ultrasonographic measures and clinical events.
Results Mean target LDL-C and SBP levels for both groups were reached and maintained. Mean (95% confidence interval) levels for LDL-C in the last 12 months were 72 (69-75) and 104 (101-106) mg/dL and SBP levels were 117 (115-118) and 129 (128-130) mm Hg in the aggressive vs standard groups, respectively. Compared with baseline, IMT regressed in the aggressive group and progressed in the standard group (–0.012 mm vs 0.038 mm; P < .001); carotid arterial cross-sectional area also regressed (–0.02 mm2 vs 1.05 mm2; P < .001); and there was greater decrease in left ventricular mass index (–2.4 g/m2.7 vs –1.2 g/m2.7; P = .03) in the aggressive group. Rates of adverse events (38.5% and 26.7%; P = .005) and serious adverse events (n = 4 vs 1; P = .18) related to blood pressure medications were higher in the aggressive group. Clinical CVD events (1.6/100 and 1.5/100 person-years; P = .87) did not differ significantly between groups.
Conclusions Reducing LDL-C and SBP to lower targets resulted in regression of carotid IMT and greater decrease in left ventricular mass in individuals with type 2 diabetes. Clinical events were lower than expected and did not differ significantly between groups. Further follow-up is needed to determine whether these improvements will result in lower long-term CVD event rates and costs and favorable risk-benefit outcomes.
Trial Registration clinicaltrials.gov Identifier: NCT00047424
Author Affiliations: MedStar Research Institute, Hyattsville, Maryland (Drs B. V. Howard, Mete, Ratner, Umans, Weissman, and Zhu, and Ms Silverman); Weill Cornell Medical College, New York, New York (Drs Roman and Devereux); National Heart, Lung, and Blood Institute, Bethesda, Maryland (Drs Fleg and Stylianou); University of Arizona Health Science Center, Tucson (Dr Galloway); Black Hills Center for American Indian Health, Rapid City, South Dakota (Dr Henderson); Washington Hospital Center, Washington, DC (Dr W. J. Howard); University of Oklahoma Health Sciences Center, Oklahoma City (Drs Lee, Wang, and Yeh); Lawton Indian Hospital, Lawton, Oklahoma (Dr Poolaw); Phoenix Indian Medical Center, Phoenix, Arizona (Drs Russell and Wilson); and University of Maryland School of Medicine, Baltimore (Dr Weir).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
Oral Hypoglycemic Use and the SANDS Trial
Eva L. Evans, Rohit P. Ojha, and Lori A. Fischbach
JAMA. 2008;300(4):389.
EXTRACT
| FULL TEXT
RELATED ARTICLE
The Great Debate of 2008—How Low to Go in Preventive Cardiology?
Eric D. Peterson and Tracy Y. Wang
JAMA. 2008;299(14):1718-1720.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study
Meaney et al.
J Clin Pharmacol 2009;49:838-847.
ABSTRACT
| FULL TEXT
The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2009;53:1326-1337.
FULL TEXT
Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?
Al Badarin et al.
Mayo Clin Proc. 2009;84:353-361.
ABSTRACT
| FULL TEXT
Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.
Chhatriwalla et al.
J Am Coll Cardiol 2009;53:1110-1115.
ABSTRACT
| FULL TEXT
Atheroma volume by intravascular ultrasound as a surrogate for clinical end points.
Tobis and Perlowski
J Am Coll Cardiol 2009;53:1116-1118.
FULL TEXT
Additional Lipid Lowering Trials Using Surrogate Measurements of Atherosclerosis by Carotid Intima-Media Thickness: More Clarity or Confusion?
Stein
J Am Coll Cardiol 2008;52:2206-2209.
FULL TEXT
Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus
Hiukka et al.
J Am Coll Cardiol 2008;52:2190-2197.
ABSTRACT
| FULL TEXT
Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial
Fleg et al.
J Am Coll Cardiol 2008;52:2198-2205.
ABSTRACT
| FULL TEXT
Review: Stroke in type 2 diabetes
Sander et al.
British Journal of Diabetes & Vascular Disease 2008;8:222-229.
ABSTRACT
Risk Factors Control in Diabetes: The "Real World" of Clinical Practice
Escobar and Barrios
The Diabetes Educator 2008;34:763-764.
FULL TEXT
Oral Hypoglycemic Use and the SANDS Trial
Evans et al.
JAMA 2008;300:389-389.
FULL TEXT
New Perspectives on the Management of Type 2 Diabetes: Report of symposia at the Royal College of Physicians, London, 16 April 2008 and Hilton Hotel, Coventry, 14 May 2008
Barnett et al.
British Journal of Diabetes & Vascular Disease 2008;8:198-205.
How Low Should We Go (with BP and Cholesterol in Diabetic Patients)?
JWatch General 2008;2008:6-6.
FULL TEXT
All you need to read in the other general journals
BMJ 2008;336:856-857.
FULL TEXT
The Great Debate of 2008--How Low to Go in Preventive Cardiology?
Peterson and Wang
JAMA 2008;299:1718-1720.
FULL TEXT
Aggressive Treatment of High LDL Levels and Hypertension in Patients with Diabetes
Journal Watch Cardiology 2008;2008:1-1.
FULL TEXT
|
